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A cell fusion assay using fusion-from-without (FFWO) recombinant adenoviruses (RAds) and specific antibody showed a
role in fusion modulation for glycoprotein gO, the recently identified third component of the gH/gL gCIII complex of human
cytomegalovirus (HCMV). As in HCMV, RAd gO expressed multiple glycosylated species with a mature product of 125 kDa.
Coexpression with gH/gL RAds showed gCIII reconstitution in the absence of other HCMV products and stabilisation by
intermolecular disulfide bonds. Properties of HCMV clinical isolate, Pt, also implicated gO in cell spread. Compared to
laboratory strain AD169, Pt was resistant to gH antibody plaque inhibition, but mature gH was identical. However, the gO
sequences were highly divergent (20%), with further variation in laboratory strain Towne gO (34%). Thus, gO forms gCIII with
gH/gL, performs in cell fusion, and is a newly identified HCMV hypervariable locus which may influence gCIII’s function in
mediating infection. © 2002 Elsevier Science (USA)INTRODUCTION
Human cytomegalovirus (HCMV) is a clinically impor-
tant betaherpesvirus, and efforts to produce a vaccine,
primarily to prevent congenital infection, are reliant on a
better understanding of the virus surface glycoproteins
involved in host cell infection. Conserved glycoproteins
have been used in antibody-based diagnosis of primary
infection during pregnancy and have also showed suc-
cess as vaccines against congenital infection in animal
models (Bourne et al., 2001; Chatterjee et al., 2001; Egg-
ers et al., 2001). However, evidence has been presented
that variation in at least one of these glycoproteins can
affect infection with new strains in intrauterine transmis-
sion in women with prior immunity to HCMV (Boppana et
al., 2001). In HCMV and other herpesviruses, together
with some other enveloped viruses such as HIV, the
mechanism of entry relies on the fusion of membranes,
as does subsequent cell-to-cell spread, and is mediated
by viral envelope glycoproteins. Although cell fusion is
apparent from the cytopathic effect observed in vivo, it
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dependent, and may differ between laboratory strains
and clinical isolates (Booth et al., 1978; Jarvis et al., 1999;
Gerna et al., 2001).
To investigate further cell fusion mediated by HCMV,
an assay was developed which uses “fusion-from-with-
out” (FFWO). How does this compare to other fusion
assays developed for herpes simplex virus (HSV), for
example, such as neutralisation of syncytial strains in a
plaque assay or transient expression of glycoprotein
genes in a cell-based assay (Gompels and Minson, 1986;
Gompels et al., 1991; Turner et al., 1998)? FFWO is inoc-
ulum-derived cell fusion by HCMV, which is mediated by
virion envelope glycoproteins in the absence of virus
gene expression, as demonstrated by addition of actino-
mycin D in the assay (Milne et al., 1998). This distin-
guishes entry effects from factors involved in virus as-
sembly, exit, or other effects from over 200 genome-
encoded products which would be active in a plaque-
based assay. Moreover, a neutralisation assay based on
plaque development takes up to 2 weeks for HCMV,
whereas FFWO occurs rapidly, by 1 and 8 h for HSV and
HCMV, respectively (Falke et al., 1985; Milne et al., 1998).
In HCMV, it was first demonstrated in fibroblasts, while
best results are shown using virus prepared on primary
human embryonic lung (HEL) cells and assayed on as-
trocytoma (U373MG) cell lines. Similar to other fusionKey Words: human cytomegalovirus; cell fusion; glycop
adenovirus; neutralising antibody.
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assays, it correlates with effects of neutralising antibody
against virus glycoproteins, thereby linking the relevance
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to the infectious process (Milne et al., 1998). FFWO,
similar to the other assays, does not distinguish between
the linked functions in binding or penetration, but it does
allow for further investigation of roles of individual gly-
coprotein components and their relationship to virus-
induced cell fusion.
Recombinant adenoviruses (RAds), expressing glyco-
protein gH/gL on the surface of infected cells, were used
to examine effects on HCMV FFWO. These glycoproteins
are the major components of the gCIII complex (Gretch
et al., 1988; Kaye et al., 1992) and were shown to en-
hance fusion caused by HCMV viral membrane compo-
nents in the FFWO assay (Milne et al., 1998). This directly
showed a role for gH/gL in cell fusion. It also confirmed
previous indirect evidence, including inhibition of cell-to-
cell spread by neutralising antibodies and inhibition of
the transfer of a fluorescent probe from viral membranes
to cell membranes by either an anti-gH antibody or its
anti-idiotype (Rasmussen et al., 1984, 1988; Cranage et
al., 1988; Baboonian et al., 1989; Keay and Baldwin, 1991;
Urban et al., 1992, 1996; Simpson et al., 1993; Baldwin et
al., 2000). Moreover, this role in cell fusion is analogous
to the function of gH/gL conserved in other herpesvi-
ruses as shown in transient cell–cell fusion assays with
alphaherpesvirus glycoproteins (Turner et al., 1998;
Klupp et al., 2000; Muggeridge, 2000; Pertel et al., 2001).
Analyses of the gH/gL complex in betaherpesviruses,
HCMV and HHV-6, show roles for gL in cell surface
transport and identify betaherpesvirus-conserved do-
mains for gL binding to gH and fusion domains con-
served across herpesvirus subgroups. Similar to other
herpesviruses, gH complex formation with gL is required
for cell surface and virion location of the gH/gL complex
(Cranage et al., 1988; Kaye et al., 1992; Spaete et al.,
1993; Milne et al., 1998). Of particular note is the obser-
vation that HHV-6 gH and HCMV gL can form het-
erodimers. This highlights the importance of the gH/gL
complex conservation in all mammalian and avian her-
pesviruses studied to date with implications for effects
on pathology in the betaherpesviruses (Anderson et al.,
1996). A betaherpesvirus-specific N-terminal domain in
gH was identified which bound gL. This was established
in experiments involving coexpression of HCMV gL and
HHV-6 gH and immunoprecipitation of heterologous
complexes (Anderson et al., 1996). Further work identi-
fied a fusogenic-associated conformation in the herpes-
virus-conserved C-terminal domain (NGS/TV motif) of
HHV-6 gH which was mediated by N-terminal binding of
gL (Anderson and Gompels, 1999). This study also
showed that an N-terminal domain containing a betaher-
pesvirus-conserved FNFY motif, while not required for
interaction with gL, was required for the fusogenic con-
formation in the mature form. This was based on results
using an FNFY deletion mutant gH, which could only
react with fusion conformation recognising antibodies
while in immature glycoforms (Anderson and Gompels,
1999). This shows that complex interactions between N-
and C-terminal domains are influenced by gL binding to
gH and can also affect folding and presentation of the
fusion-associated conformation on gH during maturation
and presentation on the cell surface and virion.
Although the fusion assays and antibody results show
a role for the gH/gL complex in cell fusion, gH/gL RAds
do not mediate fusion when expressed on their own.
They only enhance fusion in the presence of HCMV
virions in the FFWO assay (Milne et al., 1998). This
implies that the gH/gL complex expressed from the RAds
is interacting with other HCMV membrane components.
A candidate for this component has recently been iden-
tified and is characterised further here. This is a third
member of the HCMV gCIII complex (Huber and Comp-
ton, 1997; Li et al., 1997). It is encoded by UL74 and has
been subsequently designated gO (Huber and Compton,
1998). This glycoprotein therefore has the potential to
affect gCIII complex assembly, maturation, and function.
Sequence analyses have also shown a positional ho-
molog of gO in other betaherpesviruses such as HHV-6.
These analyses show a betaherpesvirus-specific glyco-
protein with a high level of oligosaccharide modifications
at both N- and O-linked sites (Gompels et al., 1992;
Huber and Compton, 1998). The gO genes encode a
glycoprotein with an N-terminal signal sequence but no
further transmembrane anchor, suggesting either a se-
creted glycoprotein or anchorage via a noncleavable
signal sequence. Using HCMV gO-specific sera, studies
of the expression of the HCMV gO revealed that it was
initially processed to a 100-kDa form prior to final mod-
ification to its 125-kDa form after 3 to 6 h (Huber and
Compton, 1999). The use of endoglycosidase H in
HCMV-infected cells gave a pre-gO of approximately 54
kDa, correlating with the theoretical molecular weight of
the polypeptide backbone of the UL74-encoded product.
Heavy glycosylation of gO gives rise to a 125-kDa form
(Huber and Compton, 1999).
Glycoprotein gO was identified by direct protein puri-
fication of the gCIII complex from virus (Huber and
Compton, 1998). It is possible, therefore, that additional
products are required to mediate formation of this gH/
gL/gO complex, but no studies have yet been performed
to show reconstitution of the trimolecular complex in the
absence of virus. Furthermore, little is known about the
function of gO. A role for gO in the fusion and entry
processes has been suggested on the basis of proper-
ties of a gO deletion mutant virus (Hobom et al., 2000).
While the mutant is viable showing that gO is not essen-
tial for infection in vitro, the virus was severely impaired
in growth kinetics as well as the process of cell-to-cell
spread. This indicated a role in cellular spread, but the
exact function of gO in the infection process has not
been defined.
In this study, we use RAds and the FFWO assay to
examine the role of gO during infection. We also dem-
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onstrate using RAds that the gH/gL/gO complex can be
reconstituted without any other HCMV products. Finally,
we examine properties of a clinical isolate, a natural gH
MAb escape mutant, and show that while it has a con-
served gH/gL, it has high variation in gO which may
affect gCIII conformation and function. Further variation
is shown between laboratory strains AD169 and Towne,
thus defining a new hypervariable locus in HCMV which
can serve as a new strain marker, influence infection,
and affect vaccine formulation or efficacy.
RESULTS
Construction and characterisation of recombinant
adenovirus expressing HCMV AD169 gO
Recombinant adenovirus expressing gH and gL were
used to enhance fusion of HCMV in a FFWO assay
(Milne et al., 1998). Here we show that this RAd-ex-
pressed gH/gL interacts to form a complex (Fig. 1) sim-
ilar to that shown previously using vaccinia recombi-
nants (Kaye et al., 1992). A RAd-encoding gO was con-
structed to test interactions with the RAd-expressed
gH/gL complex and to directly show that gH, gL, and gO
are necessary and sufficient to form the gCIII complex. A
RAd comprising the HCMV AD169 UL74 gene was con-
structed and characterised. Two cloned RAds were pro-
duced, one in the coding orientation (RAd gO) and for a
negative control, the noncoding inverse orientation, “inv”
(RAd gOinv). These were used to infect MRC-5 cells and
gO expression examined by radioimmunoprecipitation
analyses.
As gO is highly modified with multiple sites for both
N-linked and O-linked glycosylation, a time-course ex-
periment was first performed to establish optimum con-
ditions for gO expression and maturation (Fig. 2). For this,
cells were infected at different multiplicity of infection
(m.o.i.’s) and radiolabelled at either 1, 2, 3, or 4 days
postinfection. Cell lysates were then immunoprecipitated
with the anti-gO antibody Bl5, which has been previously
described (Huber and Compton, 1998, 1999). Huber and
Compton identified several species of gO using the Bl5
antibody in pulse-chase experiments of HCMV-infected
cells. These forms included the 125-kDa mature form of
gO, which is present in the mature 240-kDa gCIII com-
plex; the 100-kDa immature form of gO (gO-100), which
complexes with gH-gL to form a 220-kDa precursor com-
plex (pgCIII); and the 54-kDa nonglycosylated immature
form of gO. We also detected these forms of gO in our
RAd expression system. The nonglycosylated 54-kDa
precursor form, pgO-54, was evident throughout the
time-course assay, while the levels of both the 100-kDa
and the mature 125-kDa form (gO-125) gradually in-
creased over a 3-day period (lanes 2, 3, and 4). Maximum
expression of gO was observed when cells were in-
fected at an m.o.i. of 200 and labeled 2 days postinfection
(p.i.) (lane 5). For all three m.o.i.’s tested, gO expression
levels declined 4 days p.i. (data not shown). One possi-
ble explanation for this is that the high levels of gO
expressed may have been toxic to the cells, resulting in
cell death, leading to an overall reduction in protein
expression. In addition to the gO species previously
reported by Huber and Compton (1998, 1999), we also
FIG. 2. Time course of RAd-expressed HCMV gO. MRC-5 cells were
infected with RAd-gO at varying m.o.i.’s and radiolabelled at different
times p.i. Cell lysates were immunoprecipitated with the anti-gO anti-
body and subjected to reducing SDS–PAGE. Lane 1, RAd-35 infected
cell lysate control; lanes 2, 3, and 4, RAd-gO-infected lysates of cells
infected at an m.o.i. of 100 and labeled 1, 2, and 3 days p.i., respectively;
lane 5, lysate of cells infected at an m.o.i. of 200 and labeled 2 days p.i.
FIG. 1. Immunoprecipitation of the HCMV gH/gL complex expressed
using replication-deficient recombinant adenoviruses. U373MG cells
were infected with HCMV AD169, RAd gH, RAds gH and gL, and control
RAd35, at 50 TCID50 of each RAd per cell, and immunoprecipitation
analysis performed. Three days postinfection, 35S-labeled lysates were
prepared and immunoprecipitated with the gH-specific MAb HCMV16.
Lane 1, mock infection; lane 2, RAd 35; lane 3 RAd gH; lane 4, RAd gH
and RAd gL. Lane 5 shows HCMV gH. The marks indicate gH and gL.
In lane M are the molecular weight markers. UL115 (gL) specific
expression in the infected cell preparations was confirmed by RT-PCR.
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observed several other species of gO (i.e., bands be-
tween 54- and 100-kDa forms in addition to multiple
forms surrounding gO-100 and gO-125). Glycoprotein O
is a heavily glycosylated protein with up to 23 potential
N-linked glycosylation sites and 18 potential O-glycosyl-
ation sites (Gompels et al., 1992; Huber and Compton,
1998). Thus, the additional forms that we observe may
represent differentially glycosylated species of gO pro-
duced during maturation. Some bands around 40 kDa
are also observed which may represent breakdown
products. Overall the results show that gO can be pro-
duced in this system and receives extensive posttrans-
lational modifications similar to those observed in the
infected cell.
Reconstitution of the gCIII complex
To test whether the RAd-expressed gO formed a com-
plex with gH and gL, MRC-5 cells were coinfected with
RAds gH, gL, and gO and cell lysates were immunopre-
cipitated using either the anti-gH (MAb HCMV16) or
anti-gO (Bl5) antibody (Fig. 3). As shown in Fig. 3A (lanes
2, 3, and 4), the anti-gH antibodies coprecipitated gH (90
kDa), pgH (84 kDa), gL (34 kDa), and pgL from lysates
coinfected with RAd-gH, RAd-gL, and RAd-gO (coding
orientation) or RAd-gOinv (noncoding orientation). In lane
3, in which cells were infected with RAd-gH, RAd-gL, and
RAd-gO, the darker bands underneath gH may represent
a species of gO. As shown in Fig. 3B, the anti-gO anti-
body precipitated multiple forms of gO: gO-125, gO-100,
pgO-54, and pgO-40 from cells infected with gO alone
(lane 6) or in combination with RAd-gH and RAd-gL (lane
7). The predicted polypeptide backbone mass of gO is 54
kDa (Gompels et al., 1992; Huber and Compton, 1998),
consistent with the pgO-54 observed while pgO-40 may
represent a breakdown product. The anti-gO antibody
also coprecipitated gH and a very faint band represent-
ing gL from cells coinfected with RAd-gH, -gL, and -gO
(Fig. 3B, lane 7). By contrast, bands representing gL and
any of the gO species were absent when cells were
coinfected with RAd-gOinv, -gH, and -gL (lane 8), al-
though a faint band corresponding to gH was observed.
This band appears to be background in this system,
since gH levels are substantially greater when RAd-gO is
used in the coinfection and gO is present (Lane 7). Thus,
the results of studies performed with reducing conditions
indicate the formation of a trimolecular complex similar
to results observed in virus infected cells (Huber and
Compton, 1998, 1999).
To determine directly if the gCIII complex could be
reconstituted in our assay, anti-gO immunoprecipitated
lysates were also subjected to SDS–PAGE under nonre-
ducing conditions (Fig. 3C). The mature 240-kDa gCIII
complex was observed when cells were coinfected with
RAd-gO, RAd-gH, and RAd-gL (lane 10) but not when
RAd-gOinv was used in the coinfection instead (lane 11).
Significantly, when RAd-gO-infected lysates were immu-
noprecipitated with the Bl5 antibody and subjected to
nonreducing SDS–PAGE (lane 9), we observed the 100-
FIG. 3. Reconstitution of the gCIII complex. Cells were coinfected with RAd-gH, RAd-gL, RAd-gO, and RAd-gOinv at an m.o.i. of 100, radiolabelled
2 days p.i., and subjected to immunoprecipitation using either the anti-gO or anti-gH antibodies. (A) Immunoprecipitation using the anti-gH antibody
and reducing SDS–PAGE. Lane 1, RAd-35-infected negative control; lane 2, RAd-gH and RAd-gL coinfected lysates; lane 3, RAd-gH, RAd-gL, and
RAd-gO coinfected lysates; and lane 4, RAd-gH, RAd-gL, and RAd-gOinv coinfected cells lysates. (B) Immunoprecipitation using the anti-gO antibody
and reducing SDS–PAGE. Lane 5, RAd-35-infected negative control; lane 6, RAd-gO-infected lysates; lane 7, RAd-gH, RAd-gL, and RAd-gO coinfected
cell lysates; and lane 8, RAd-gH, RAd-gL, and RAd-gOinv coinfected lysates. (C) Immunoprecipitation using the anti-gO antibody and nonreducing
SDS–PAGE. Lane 9, RAd-gO-infected cell lysates; lane 10, RAd-gO, RAd-gH, and RAd-gL coinfected cell lysates; and lane 11, Rad-gOinv, RAd-gH, and
RAd-gL coinfected cell lysates.
284 PATERSON ET AL.
to 125-kDa gO mature forms but no other higher molec-
ular weight forms indicative of gO multimers. The mono-
meric form of gO was only removed when expressed
with gH/gL, as shown in lane 10, indicating disulfide
bonds in the heterooligomer, but little evidence for gO
homodimer. Background bands were indicated by lane
11 control of gO in the wrong coding orientation. Thus,
the 240-kDa species under nonreducing conditions is
consistent with intermolecular disulfide bonds mediating
a covalent interaction of gH, gL, and gO to form the gCIII
complex. Using a vaccinia expression system the HCMV
gH/gL complex has been previously shown to form a
heterodimer stabilised by disulfide bonds, although gH
on its own does not form a homodimer (Kaye et al., 1992)
and similar results were found using the RAd system
(data not shown). The lack of a prominent homodimer for
either HCMV gO or gH contrasts with HHV-6 gH which
clearly forms a homodimer under similar conditions
(Anderson et al., 1996).Taken together, these results in-
dicate that whereas gO, similar to HCMV gH, does not
form disulfide bonds with itself, it does form disulfide
bonds with gH/gL to form a trimolecular gCIII complex.
Formation of the mature gCIII HCMV gH/gL/gO complex
formation has been demonstrated previously in HCMV-
infected cells (Huber and Compton, 1998, 1999). How-
ever, by using a recombinant adenovirus expression sys-
tem, we demonstrate for the first time gCIII reconstitution
in the absence of the HCMV virion particle. This sug-
gests that additional HCMV virion products are not re-
quired for these interactions. Thus, HCMV gH/gL/gO are
necessary and sufficient to form this tripartite gCIII com-
plex.
Inhibition of fusion by anti-gO antibodies
As gH, gL, and gO were shown competent at complex
formation using the RAd system, the FFWO assay was
used to analyse a role for gO in fusion. Anti-gO antibod-
ies (Huber and Compton, 1998, 1999) were incorporated
into the fusion assay to examine possible roles as pre-
vious results using specific antisera had shown roles for
gH as well as gB (Milne et al., 1998). Specific gO rabbit
serum was added at dilutions of 1:30, 1:100, and 1:300 to
fusogenic AD169 (titers of between 105 and 106 TCID50/
ml). The positive control was HCMV16 (HCMV gH-spe-
cific), which has been shown previously to inhibit fusion
of both the virus and the FFWO assay (Cranage et al.,
1988; Milne et al., 1998). The negative controls included
normal rabbit sera and C13 (HCMV pp65-spe-
cific), which is nonneutralising and does not inhibit fu-
sion of the virus or the FFWO assay (Cranage et al., 1988;
Milne et al., 1998). Using methods shown previously in
the FFWO assay, fusogenic AD169 virus (prepared on
HEL cells) was used to superinfect U373MG cells previ-
ously infected with various combinations of gH, gL, or
control RAds. These were then treated with the antibod-
ies in the overlaying media together with actinomycin D
to prevent gene expression. After 16 h incubation, the
plates were fixed and the cells were examined. The
results show specific inhibition of fusion of the U373MG
cells by the anti-gO sera (Fig. 4). Quantification of the
results showed specific fusion with an endpoint beyond
a 1:100 dilution (Fig. 5). The fusion inhibition achieved
using the polyclonal anti-gO antibodies at a 1:30 dilution
was similar to that observed with the gH-specific
HCMV16 antibodies as ascites fluid diluted 1:100. The
result was specific as no inhibition was observed with
nonimmune sera or with nonneutralising HCMV pp65
antibodies. This demonstrates that gO has a role in cell
fusion as assayed by FFWO.
A clinical isolate resistant to plaque inhibition by gH
antibody and a divergent gO
In vivo evidence for a function for gO in cellular spread
was explored. A clinical HCMV isolate, strain Pt, was
further investigated which had unusual properties in cell
spread and reactions with neutralising gH-specific anti-
bodies. Strain Pt had identical single-cycle growth kinet-
ics to laboratory strain AD169, but over multiple cycles
(i.e., when the m.o.i. was very low,  0.02/cell) was
impaired, and grew to titers 100-fold less than AD169.
This indicated an alteration in the cell-to-cell spread
pathway, but not the virus entry pathway. Consistent with
this result, this clinical isolate was resistant to gH-spe-
cific antibody, MAb C2 (Baboonian et al., 1989), in plaque
inhibition assays designed to measure cell-to-cell
spread (Fig. 6A). Similar results were shown for gH MAb
14.4b. The resistance to antibody-mediated plaque inhi-
bition was specific for these gH MAbs, while neutralising
human immune sera was still active against strain Pt in
the plaque inhibition assays.
However, infection with cell-free virus, as opposed to
infected cell-to-cell spread, was neutralised efficiently by
MAb C2 (Fig. 6B) with similar results using other gH
neutralising MAbs 14.4b, 1G6 and HCMV16. Moreover
the virus encoded a gH with a mature amino acid se-
quence identical to AD169 (Accession No. Q68571).
There were no detectable differences in surface or intra-
cellular immunoprecipitated gH and kinetics of entry
were indistinguishable between Pt and AD169 (not
shown). Thus, this clinical isolate may have an alterna-
tive, gH-independent mechanism for cell-to-cell spread
in the presence of MAb C2. Alternatively, since this is a
conformational sensitive MAb, changes in the other com-
ponents of the gCIII complex, such as gL or gO, may
affect conformation and function in cell spread by fusion
and may indicate some selection with antibodies to gCIII.
Analyses of the Pt gL sequence only showed limited
differences. These included six conservative amino acid
substitutions (Accession No. Q68666). Moreover there
were no significant differences between gL of AD169 or
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Pt in the fusion assay. When Pt or AD169 gL were used
to achieve surface expression of gH, the extents of en-
hanced fusion in the FFWO assay performed previously
(Milne et al., 1998) were similar with AD169 gL  714
(SD 131) compared here to Pt gL 808 (SD 98); P
0.0656. Furthermore, there were no differences in medi-
ating cell surface expression of gH as assayed by im-
munofluorescence. The phenotypic changes may be due
to differences in the third gCIII component, gO.
The sequence of the UL74, gO, gene from strain Pt was
determined and compared to that of laboratory strain
AD169. The results showed a remarkably high degree of
variability (20%). This was pronounced at the N-terminal
end, while the C-terminal region showed higher conser-
vation (40% N-, 6% C-terminal divergence) (Fig. 7). There
were 1–3 nucleotide deletions and insertions together
with mismatches in the N-terminal region, and while the
C-terminal region was conserved there was a prominent
9 nucleotide deletion in strain Pt compared to AD169,
resulting in loss of an encoded N-linked glycosylation
site. The overall divergence observed supported the in-
terpretation that the gO product was most likely to ac-
count for differences in the phenotype of the gCIII com-
plex in reaction to the C2 antibody. This was further
investigated by analyses of amino acid sequences and
gO of another reference laboratory strain.
Previous studies of gH variation in HCMV had shown
5% divergence with AD169-like viruses most distinct from
FIG. 4. Enhanced HCMV induced fusion of U373MG cells using RAds gH/gL and fusion inhibition with gO antisera. Anti-gO antibodies (Huber and
Compton, 1998) were incorporated into the FFWO assay to examine any inhibitory property they may have. U373MG were infected with RAds gH and
gL then superinfected with fusogenic AD169 as described under Materials and Methods. Rabbit serum specific for gO was added at dilutions of 1:30,
1:100, and 1:300. Controls included HCMV16 ascites (gH-specific; 1:100), which were shown previously to inhibit fusion, and negative control C13
(pp65-specific), which is nonneutralising and does not inhibit fusion, and nonimmune rabbit sera were employed as controls. Examples of fusion
observed are shown as follows: (A) no antibody; (B) gH neutralising antibody, (C) gO antibody 1:100, (D) gO antibody 1:300, (E) nonimmune rabbit sera,
(F) gO antibody 1:30. Complete inhibition of fusion are shown with gH 1:100 and gO 1:30 antibodies (B, F).
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Towne-like viruses (Chou, 1992). As the gH and gL genes
from strain Pt were both closely related to strain AD169,
it was possible that the divergence in gO represented a
recombinant with a Towne-like strain. This was exam-
ined by deriving the nucleotide sequence of gO from
laboratory strain Towne. Surprisingly, the results showed
that the strain Pt gO remained most closely related to
laboratory strain AD169, while strain Towne gO was even
further divergent. Towne gO showed only 66% amino
acid sequence identity in multiple alignment and dendro-
gram analyses and included greater nonsynonymous
changes which are indicative of selection (Fig. 8). Thus,
the sequence comparisons demonstrate that gO is a
new hypervariable site in HCMV and indicate that
changes in this gene may affect infectious spread.
DISCUSSION
We have investigated properties of HCMV gO and
show directly using RAds that coexpression of gH, gL,
and gO is necessary and sufficient to form a trimolecular
complex consistent with the gCIII complex produced by
the virus. Therefore, complex formation can occur in the
absence of any other HCMV products. We also show that
gO has a role in virus-mediated cell fusion as shown by
fusion inhibition using gO-specific antibodies in the
FFWO assay.
A role for gO in cell fusion is supported by the behavior
of the clinical isolate, strain Pt, which is a naturally
occurring antibody-escape mutant, resistant to inhibition
of cell-to-cell spread by gH-specific neutralising MAbs.
Sequence analyses of the gCIII genes suggests this
phenotype is most likely due to a highly divergent gO
(20% coding changes overall and 40% divergence in the
N-terminal region), as Pt gH is identical to that of AD169.
Although Pt gL had minor conservative substitutions, it
remained functionally equivalent in gH complex forma-
tion, gH cell surface chaperone capacity, and the gH/gL
fusion enhancement in the FFWO assay. Other major
changes in the Pt gO sequence include a 9-nucleotide
deletion in the C-terminal conserved domain which re-
sults in the lack of an encoded site for N-linked glyco-
FIG. 5. Quantification of fusion enhancement with RAds gH/gL and
inhibition by gO antibodies. Extent of fusion was measured as de-
scribed under Materials and Methods and results are presented from
triplicate experiments. The fusion axis shows the number of nuclei
within syncytia per well as measured from four random views (two
fields each from two duplicate wells) of 50 magnification, photo-
graphed, screen projected, and counted blind from coded images. The
fusion results are shown for each antibody condition indicated in sets
of no RAd (black shading), RAd-gH (no shading), or RAds gH/gL (gray
shading). Set 1 has no antibody treatment; set 2, gH neutralising
antibody; set 3, pp65 antibody; set 4, nonimmune rabbit sera 1:30; set
5, gO antibody 1:30; set 6, gO antibody 1:100; and set 7, gO antibody
1:300.
FIG. 6. HCMV clinical isolate, strain Pt, is resistant to antifusion gH antibodies but remains sensitive to gH cell-free virus neutralising antibodies.
(A) Plaque inhibition assay. This assay measures inhibition of cell-to-cell spread (plaque inhibition) by gH antibody in the overlaying media; the results
are from 2 weeks postinfection. Mean plaque size in the presence of gH MAb C2 was expressed as a percentage of mean plaque inhibition calculated
by comparing plaque size in the presence of nonneutralising structural pp65 MAb C13. Each point on the graph represents a single experiment, and
is shown in quintuplicate. The mean percentage value for each strain is shown with an error bar indicating 1 SD. The two means were significantly
different by the Student’s t test (P  0.0001). (B) Cell-free virus neutralisation assay. This assay measures inhibition of virus survival after cell-free
virus is incubated with gH antibody and then titrated in the absence of antibody. The mean percentage of survival for each strain of virus at each
dilution of gH MAb C2 is shown (n  4). Error bars represent  SE.
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sylation (at positions 400–403 of AD169), which could
also affect conformation or function.
Interestingly, strain Pt also had a defect in cell-to-cell
spread, giving rise to a small plaque phenotype. Al-
though there may be other factors than the Pt gO allele,
these results are consistent with properties of a recently
described HCMV gO deletion mutant. These viruses
have reduced plaque size and poor growth kinetics,
yielding titers reduced by about 1000-fold (Hobom et al.,
2000). Both this result, and the fact that anti-gO antibod-
ies inhibit HCMV-induced cell fusion as shown here,
indicate that gO plays a role in cellular spread mediated
by membrane fusion.
Hobom et al. also showed that gH was essential for
infection (Hobom et al., 2000), consistent with the results
of a number of previous studies using gH-specific neu-
tralising antibodies (Rasmussen et al., 1984, 1988; Cra-
nage et al., 1988; Keay and Baldwin, 1991; Simpson et al.,
1993) and by analogy to other herpesviruses (Gompels
and Minson, 1986; Gompels et al., 1991; Forrester et al.,
1992; Roop et al., 1993). It is likely, therefore, that gH is
the primary functional component of gCIII in terms of
modulation of fusion as also demonstrated by the fusion
enhancement with gH/gL in the FFWO assay (Milne et
al., 1998). The results shown here together with those of
Hobom et al. indicate that gO plays an important syner-
gistic role in cell-to-cell spread or can direct an alterna-
tive pathway. Preliminary results on using RAds to ex-
press the gO/gH/gL and probing further the relationship
to fusion suggest other membrane components are re-
quired for complete fusion, possibly a binding role such
as from gB as described for homologues in the HSV
fusion assay (Turner et al., 1998). As noted previously,
HCMV gB sera does inhibit the FFWO fusion assay
(Milne et al., 1998).
HCMV may use gO for infection of only certain cell
types. Different gH/gL complexes mediate infection of
different cell types in Epstein–Barr virus (EBV), the only
other herpesvirus that has been shown to include a third
component in its gH/gL complex. EBV uses the BZLF2
gene product (unrelated to HCMV UL74 gO) as the third
component of the EBV gH/gL complex. Recent evidence
FIG. 7. Strain Pt has a divergent gO. Nucleotide sequence of strain Pt gO compared to that of laboratory strain AD169. The vertical lines indicate
two main regions of divergence, the N-terminal region which has 40% differences containing small deletions and insertions, and a larger 9 nucleotide
deletion within the conserved C-terminal domain.
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shows that BZLF2 mediates binding to the MHC Class II
molecule, and consistent with this result, the BZLF2
containing gH/gL complex is essential for EBV infection
of B lymphocytes. However, BZLF2 is not required for
infection of epithelial cells, where the bimolecular gH/gL
complex is sufficient for virus entry and may utilise a
distinct cellular receptor (Li et al., 1995; Wang et al., 1998;
Molesworth et al., 2000). HCMV infects many cell types;
it may therefore only require gO for cell-to-cell spread by
fusion with some of these. Studies, as performed by
Hobom et al. in MRC-5 cells (Hobom et al., 2000), would
be required in many different cell types to examine this
further.
From the above results, it is possible that gO mediates
a role in cellular spread which may be distinct from
processes during initial virion infection. There is evi-
dence that individual roles of glycoproteins in these
mechanisms may differ potentially due to different pre-
sentation in the cell-free virion vs infected cell mem-
branes. In HSV-1 for example, MAb gH escape mutants
have different sensitivities to gH neutralising antibody in
the presence of wild-type gH provided in the virion or the
infected cells. This was done using either infections or
plaque assays on wild-type gH producing cell lines
(Gompels et al., 1991). Furthermore, some HSV-1 gD
MAbs inhibit only cell-to-cell spread (Minson et al., 1986).
Similarly, EHV-1 gp300-specific antibodies reduced
plaque size and prevented fusion of infected cells but did
not affect infectivity (Whittacker et al., 1992; Wellington et
al., 1996). Moreover, HHV-6 gH specific MAbs show dis-
tinct properties in either neutralising infection alone or
combined with inhibition of cell-to-cell spread in syncytia
formation (Foa-Tomasi et al., 1991; Liu et al., 1993; Ander-
son and Gompels, 1999). Furthermore, Wilson et al.
(1994) showed a V831-A mutation in HSV-1 gH alters only
the cell surface (as opposed to virion) gH phenotype, and
no longer permits syncytium formation, while still allow-
ing virus entry. Cell fusion defects were also shown for
several linker scanning mutations in the C-terminal do-
main of HSV-1 gH (Galdiero et al., 1997). In studies on
HCMV, Li et al. characterised another natural human gH
MAb escape mutant, which similar to strain Pt, also did
not have changes in the coding region of the gH gene (Li
et al., 1995). In this case, the level of gH expressed on the
virion was reduced. In light of the results with the HCMV
clinical isolate Pt, it would also be of interest to charac-
terise the gO gene of this virus and the possible role in
maturation of gH.
Since gO is either secreted or anchored by its N-
terminal signal sequence, it does not have an internal
cytoplasmic domain, thus differing markedly from gH.
Recent data from transient expression analyses show
that this signal sequence can be cleaved, and thus,
similar to gL, the mature gO molecule may be secreted
or membrane bound in association with gH (Theiler and
Compton, 2001). The cytoplasmic domain in gB has been
shown to have a nuclear localisation signal that permits
nuclear envelope localisation, a site for virion envelop-
ment (Meyer and Radsak, 2000). This mechanism for
nuclear envelope localisation is not possible for gO;
furthermore, the gH/gL complex has been shown to form
prior to the addition of gO (Huber and Compton, 1999).
Thus, presentation and function in the different mem-
branes of the infected cell and the cell-free virus are
likely to differ and can affect their roles in fusion, infec-
tion, and cellular spread. There may be many more
FIG. 8. Sequence of Towne gO shows a hypervariable locus. (A)
Multiple sequence alignment of gO amino acid sequences from labo-
ratory strain Towne compared to strain AD169 and clinical isolate strain
Pt. Hydrophobic sequences at the N-terminal end of gO are underlined
and are predicted to form part of the signal sequence/transmembrane
domain. N-linked glycosylation sites are also underlined. (B) Dendro-
grams showing relationship between nucleotide (UL74) and encoded
amino acid sequences of gO from Towne, AD169, and Pt strains.
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glycoproteins which modify the infectious process in
HCMV, with over 50 encoded glycoprotein genes and
additional variation observed in passages of laboratory
strains, for example, the large deletions recently ob-
served (Cha et al., 1996; Dargan et al., 1997). This study
does highlight the importance of the gCIII complex and
show that both gH and gO have a role in infection by cell
fusion but exact contributions may differ, possibly in
different membranes or cell types and within different
strain backgrounds.
Our results also show that the gO, UL74, gene defines
a new hypervariable locus in HCMV with over 34% diver-
gence. Similarly, the related betaherpesvirus HHV-6 also
encodes a gO homolog which is a site of genomic
variation. In contrast the other members of the HCMV
gCIII complex, gH and gL (UL75 and UL115, respec-
tively), are relatively conserved genes, with only up to 5%
divergence, with similar results also for the HHV-6 gH/gL
homologues (Chou, 1992; Gompels et al., 1993; Spaete et
al., 1993; Kasolo et al., 1997; Dominguez et al., 1999). The
divergent gO gene is located adjacent to the conserved
gH gene and is also a site of recombination and diver-
gence between herpesvirus species (Gompels et al.,
1992, 1995; Huber and Compton, 1998). Similarly, the
conserved gL gene is located adjacent to a divergent
region encoding hypervariable chemokine genes
(French et al., 1999), which is also within a genomic
region for recombination and divergence between her-
pesviruses. In the HCMV genome, this region is adjacent
to a large deletion in laboratory strains, with clinical
strains encoding additional potential virulence genes,
including the variable UL144 open reading frame, which
encodes a tumor necrosis factor receptor homolog (21%
divergence between the encoded proteins of different
isolates) (Lurain et al., 1999). Recent results have also
identified gN as another betaherpesvirus variable loci
(Dal Monte et al., 2001). This glycoprotein forms a com-
plex with the conserved gM, which in other herpesvi-
ruses is a fusion modulator (Klupp et al., 2000; Mach et
al., 2000) and is encoded by UL73 just upstream of the
UL74 gO gene and at a breakpoint for rearrangement
between herpesvirus species (Gompels et al., 1995).
Thus, these regions of divergence add accessory func-
tions specific for individual herpesvirus species and can
contribute to their virulence.
In conclusion, these studies show that gO is neces-
sary and sufficient for the interaction with gH/gL to form
the gCIII complex. It is a fusion-related gene product
involved in cellular spread and is a hypervariable site
which may contribute to virus virulence. It will be of
interest in future work to further determine contact sites
between the gH/gL/gO gCIII complex and their relation-
ship to cell fusion, variation, and influence on infection
and vaccine strategies. Recent results on intrauterine
transmission show that variation in gH correlates with
infection with additional HCMV strains in mothers with
prior immunity (Boppana et al., 2001). Our results suggest
that gO warrants investigation in these or related studies
and may be a potent determinant of transmission given
its interaction with gH/gL, high variation, and role in cell
fusion.
In previous work, we have shown heterologous gH/gL
complex formation between the betaherpesviruses
HCMV and HHV-6 (Anderson et al., 1996). Preliminary
data also suggest this complex is functionally competent
in an HHV-6-based FFWO assay using HCMV gH/gL
RAds, implicating heterologous interactions with HHV-6
gO. Thus, the relationship between complex formation,
cell fusion, and infection can now be further investigated.
This has biological implications for each betaherpesvi-
rus, as well as in cases where these viruses frequently
co-reactivate, and can co-react, such as in immunosup-
pressed transplant and HIV/AIDS patients (Fillet et al.,
1996; Ratnamohan et al., 1998; Emery et al., 1999; Humar
et al., 2000; Takemoto et al., 2000; Mendez et al., 2001).
MATERIALS AND METHODS
Cells, viruses, and antibodies
U373MG astrocytes, human foreskin fibroblast cells
(HFFF, CB1945), human embryonic kidney 293 cells, and
MRC-5 cells were obtained from the European Cell and
Culture Collection (ECACC; Porton Down, Wilts, U.K.).
HEL12469 fibroblasts were prepared from fetal lung tis-
sue and shown to be free from mycoplasma infection at
the Clinical Virology Laboratory, St. George’s Hospital
Medical School and deposited with ECACC. Cells were
cultured in Eagle’s minimum essential medium (EMEM;
ICN Biomedicals Inc.; Cat. No. 12-102-54, supplied lack-
ing L-glutamine), and supplemented with 10% foetal bo-
vine serum (FBS; Gibco BRL; Cat. No. 10081-164), 2 mM
L-glutamine (ICN Biomedicals; Cat. No. 16-801-49, sup-
plied as a 200-mM stock solution), 50 IU/ml penicillin,
and 50 g/ml streptomycin (ICN Biomedicals; Cat. No.
16-700-49, supplied as a 100 concentrated stock solu-
tion), nonessential amino acids (NEAA; Sigma, supplied
as a 100 concentrated stock solution; 293 cells and
U373MG only), and 1 mM sodium pyruvate (Gibco BRL;
Cat. No. 043-01360H, supplied as a 100-mM stock solu-
tion; U373MG only).
HCMV laboratory strain AD169 was a subculture of a
former candidate live vaccine, used below passage 5
(Elek and Stern, 1974). It was propagated in HFFF
CB1945 cells and for fusion assays it was passaged
once in HEL12469 fibroblasts. Titrations were as de-
scribed previously (Steel et al., 1988; Milne et al., 1998).
Clinical HCMV strain Pt was isolated from a routine
sample from the St. George’s Hospital Diagnostic Virol-
ogy Department and was used previously as a control for
a rapid HCMV culture diagnostic test (Steel et al., 1988).
This virus grew with similar single-cycle kinetics to
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AD169 (data not shown), unlike many clinical HCMV
isolates characterised in the Diagnostic unit.
The HCMV gH-specific monoclonal antibody (MAb)
HCMV16 (Cranage et al., 1988) was obtained from Co-
gent Diagnostics and the gO-specific polyclonal rabbit
sera, Bl5 (Huber and Compton, 1998, 1999), was gener-
ously provided by Professor Teresa Compton, University
of Wisconsin. The gH-(C2) and pp65-(C13) specific MAbs
have been described previously (Baboonian et al., 1989).
Samples of gH MAbs 14.4b and 1G6 were kind gifts of
Professors Bill Britt, University of Alabama, and Lucy
Rasmussen, Stanford University, respectively (Rasmus-
sen et al., 1984; Bogner et al., 1992).
Virus antibody neutralisation and plaque inhibition
assays
HFFF cells in 24-well dishes were infected with 50–
100 PFU of HCMV strains AD169 or Pt, after 1 h absorp-
tion at 37°C, 1 ml of semisolid agarose was added
containing 0.4% (w/v) agarose and either gH MAb C2 or
the control nonneutralising pp65 MAb C13. Both MAbs
(mouse ascites fluid) were incorporated at a dilution of
1/500 (this dilution of C2 can neutralise 90% of virus prior
to absorption). Plates were incubated for 2 weeks at
37°C then fixed and stained using immunoalkaline phos-
phatase detection as described (Steel et al., 1988).
Plaque size was measured by screen projection using a
microfilm reader and averaged for each treatment.
Neutralisation of infectivity of cell-free virus by anti-
body was detected by a reduction in virus titer following
exposure to antibody. Serial 10-fold dilutions of MAb C2
and MAb C13 at 103 dilution were prepared in growth
medium, mixed with an equal volume (250 l) of medium
with 100 PFU of HCMV strain AD169 or Pt, and incubated
at 37°C for 1 h. The virus/MAb mixtures were then plated
in duplicate onto HFFF monolayers, incubated for 14
days under a semisolid overlay, fixed, and stained as
above. For each virus, the mean number of PFU at each
dilution of C2 was expressed as a percentage of the
mean number of PFU in the C13 control wells.
Recombinant adenovirus
The HCMV RAd gH has been described previously
(Milne et al., 1998). RAds AD169 gL and AD169 gO in
coding and inverse noncoding orientations were con-
structed with similar methods using E1 deleted replica-
tion-deficient RAd, except construction of RAd AD169 gO
employed the one-step vector, pCA14 (Microbix, Canada)
in place of pMV100/pMV60. The UL74 gene was ampli-
fied from HCMV strain AD169 virion DNA using PFU
polymerase with the following primers modified to con-
tain BamHI restriction enzyme sites: UL74-1 5 CGGT-
GCGGGGGATCCTCCTCTGTC 3; UL74-2 5 GACATT-
GCTGGATCCAGAACTTTA 3. The amplified product was
digested with BamHI, gel purified, ligated with BamHI-
digested phosphatased pCA14, and transformed into
Escherichia coli strain JM109. The resulting plasmid was
cotransfected with pJM17 into E1 complementing 293
cells to produce recombinant adenovirus RAd gO and
cloned by limiting dilution as described previously (Milne
et al., 1998). Control RAd35 (which expresses Esche-
richia coli lacZ) was a generous gift of Dr. Gavin Wilkin-
son (Department of Medicine, University of Wales,
Cardiff, U.K.).
DNA sequencing and analyses
Sequencing of AD169 gH and Pt gH were as described
(Milne et al., 1998). Plasmid pMV100 AD169 and Pt gL
sequences were determined using a Li-cor 4000LS au-
tomated sequencer, and reactions were performed using
Thermosequenase (fluorescent-labeled primer cycle se-
quencing kit following the manufacturer’s protocol (Am-
ersham)). UL115 sequencing primers were for both cod-





UL115-B 5AGGGCATCACACTCT3; UL115-C 5TCG-
AAGCCTAACACG3; UL115-D 5CAGCATCTTCACGGA3
UL115-E 5CGAGCCATCGCCGCA3 UL115-F 5GCT-
GACGCTGTTGAG3; UL115-G 5AGTGTCCAGGAAAGC3
UL115-H 5CCGTTGGTGAATGTT3 UL115-I 5CACCCAA-
CAGGCATC3; UL115-J 5TGTTTCCTCAGTCGC3.
Sequencing of plasmid DNA or PCR products (UL74)
from strain Pt, AD169, and Towne were performed using
a Perkin–Elmer ABI sequencer. Primers used for se-




UL74-5 5-TACTACCGCCGCAAG-3 UL74-7 5-GTTCGGTT-
GCGGCTT-3; UL74–9gO2 5-AGACAAGTCATGGAAGG-3
UL74-10 5-TTGCCTATCTTAGAC-3; gO1 5-CTCCTCTGT-
CATGGGGAGAAA-3; F1A 5-AGTTTCCCCCGAATTC-
CATTTTAG-3; F2 5-AGTTTTTACCTGGTTAACGCC-3; F3
5-ACCGCCGTATCAGAATTTATG-3; R1A 5-TTGACAG-
GCGCTTGTTTAC-3; R2 5-GGAAGCCGTTTCGTTTTC-
CAC-3; R3 5-TTACTGCAACCACCACCAAAG-3 gO F4
5 CCG TAC ACT ATT TAC GGT A 3; gO R4 5 CTC ATC
GTC CAG CTT TGC G 3 A primer specific for the major
immediate early promoter contained in the plasmid vec-
tor was also used to confirm 5-terminal sequences on
inserted genes gO and gL, MIEP (HCMV) 5CGCAAAT-
GGGCGGTAGGCGTG3.
Results were collected and the electrophorerograms
examined to compile the final sequence. When PCR
products were sequenced, three independent sequenc-
ing reactions were run from different PCR reactions,
which had been performed using PFU polymerase, to
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give good fidelity. Results presented are consensus se-
quences derived from such experiments. The sequences
were compiled from the results of bidirectional sequenc-
ing using Perkin–Elmer ABI Sequence Navigator. Multi-
ple alignments were produced based on CLUSTAL anal-
yses and dendrograms were generated from these re-
sults (Higgins and Sharp, 1989). The Pt and Towne gO
sequences are deposited in GenBank/EMBL databases.
Cell fusion assay
This has been described in detail elsewhere (Milne et
al., 1998). Briefly, U373MG cells were seeded in 96-well
plates (Falcon) (5  104 per well) and infected the fol-
lowing day with approximately 50 TCID50/cell RAd gH or
RAd gH and gL. At 72 h postinfection, cells were super-
infected with fusing AD169 (prepared in HEL12469 cells,
titer between 105 and 106). Actinomycin D, 25 g/ml
(Sigma), and relevant antibodies were added at the ap-
propriate dilutions. Control HCMV16 gH MAb ascites
was diluted 1:100, and several dilutions of the gO anti-
body were used as noted in the text. Plates were centri-
fuged at 800 g for 15 min at room temperature (Heraeus
SEPATECH Labofuge 400E, rotor 8177) prior to overnight
incubation (14–16 h) at 37°C. Medium was then removed
and cells were fixed for 10 min in methanol and stained
for 1 h in Giemsa (1:20 dilution; Sigma, Cat. No. GS-500).
Following bench-top air-drying, wells were viewed and
the fusion quantified as previously described using pro-
jected cell images and counting nuclei in fused syncytia
(Milne et al., 1998). This quantification is similar to that
used for a herpesvirus “fusion-from-within” cellular assay
(Turner et al., 1998).
Radioimmunoprecipitation assay
MRC-5 cells grown in 25-cm2 flasks were infected with
RAds at an m.o.i. of either 50, 100, or 200. At 1–4 days
postinfection, cells were labeled overnight with 50 Ci
[35S]methione (1000 Ci/mmol, Amersham) in methio-
nine-deficient media (ICN). Labeled cells were washed
two times in ice-cold PBS, lysed with cold RIPA buffer
(150 mM NaCl, 50 mM Tris–HCl (pH 7.5), 1% Nonidet
P-40, 1% sodium deoxycholate, 1 mM EDTA) and cell
debris pelleted by centrifugation at 13,000 rpm for 30 min
at 4C. For immunoprecipitation of the gCIII complex,
RAd-infected lysates were rotated with 1–2 l of the
appropriate antibody for 2 h at 4C. Immune complexes
were incubated with Protein A–Sepharose for an addi-
tional 2 h at 4C, washed three times with 0.5 ml of RIPA
buffer with half-strength detergents as described (Ander-
son et al., 1996) and once with 25 mM Tris (pH 7.4). For
the RAd-gO time course, infected cell lysates were im-
munoprecipitated using the IMMUNOcatcher Kit accord-
ing to the manufacturer’s instructions (CytoSignal Re-
search Products). Immunoprecipitates were resus-
pended in sample buffer and subjected to SDS–PAGE on
precast 4–12% minipolyacrylamide gels (Novex) under
denaturing, reducing, or nonreducing conditions as de-
scribed previously (Anderson et al., 1996). Gels were
fixed and treated with Amplify (Amersham) for 15 min
prior to exposure to Hyperfilm (Amersham) for autora-
diography.
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